James Madison University recognizes the importance of conducting a broad
spectrum of original problem-solving research which requires the use of
recombinant DNA technology.
Cognizant that these activities may be accompanied
by some risks, the University requires that the activities by this policy
be reviewed and approved by an Institutional Biosafety Committee (IBC) to
ensure that it is conducted in accordance with the National Institutes of
Health Guidelines For Research Involving Recombinant DNA Molecules as published
in the Federal Register on 7/5/1995.
This policy is in full compliance with
the applicable federal and state laws and regulations. In addition, adherence
to this policy shall not exempt investigators employing recombinant DNA
molecules in their research from compliance with other applicable laws,
regulations or policies (e.g. research with human subjects or research with
animals).
